Migraine

Discover how Vyepti revolutionizes migraine prevention with rapid efficacy and strong safety, empowering pharmacists to enhance patient care.

The approved injection contains dihydroergotamine (DHE), which is the same medication used in hospitals, in a ready-to-use device.

In clinical trials, the dihydroergotamine (DHE) nasal powder had favorable safety profiles and rapid pain relief in patients with migraine with or without aura.

Traditional risk factors were more contributable to cryptogenic ischemic stroke (CIS) without patent foramen ovale (PFO), whereas nontraditional ones were more critical for CIS with PFO.

Numerical differences were observed as early as Month 1.

Meloxicam and rizatriptan reduces migraine pain and help patients return to normal functioning with efficacy through 24 to 48 hours after a single dose for some patients.

In addition, pharmacists can screen for potential contraindications and drug-drug interactions.

The updated recommendations include CGRP inhibitors as a first-line treatment option for chronic and episodic migraine prevention.

Migraine is a chronic neurological disease characterized by throbbing or pulsating unilateral or bilateral headache that can last from hours to days.

The FDA assigned a Prescription Drug User Fee Action date is January 31, 2025.

The authors determined that 40 patients (74.1%) converted from chronic to episodic migraine.

In a meta-analysis, high-dose eicosatetraenoic acid and docosahexaenoic acid had the highest efficacy and lowest dropout rate among pharmacological interventions for migraine.

The AAN speaker highlights what health care providers need to know when treating migraines in populations on hormone therapy, as well as how hormones can influence migraines.

With migraine as a leading disability for those under the age of 50, treatment options for migraine should be personalized to the patient and their needs.

The extension trial of atogepant demonstrated an 8.5-day improvement of monthly migraine days at weeks 13 through 16 and no new safety signals were observed.

As a CGRP receptor antagonist, zavegepant intervenes during the active phase of migraine, providing a targeted and prompt response to alleviate symptoms.

Be of value to patients and caregivers in forming a care plan for this challenging condition

Migraines are not a one-size-fits-all condition, and there is no one-size-fits-all solution.

Stress may have more of an effect on migraines than COVID-19 infection or vaccination.

Three classes of drugs could be 2 to 5 times more effective than ibuprofen for the treatment of migraine attacks, according to results of a study.

Zavegepant (Zavzpret; Pfizer) is the first and only only CGRP receptor antagonist as a nasal spray for the acute treatment of migraine in adults with and without aura approved by the FDA.

Pharmacists can make clinical recommendations tailored to patients’ individual needs.

Study investigators observed no significant differences in oxygen supplementation, hospitalization, or COVID-19 related death between initiators and non-initiators, though they cautioned more research was needed.